Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging — REALM

Intracranial Arterial Stenosis Clinical Trial

Official title:
Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging in Two Years

Status Completed

Clinical Trial Summary

1. It is a multicenter, open-label, sing arm study to evaluate the effects of treatment of Rosuvastatin 10-20mg in volume and morphology of atherosclerotic plague by reducing LDL-C level to or less than 70mg/dl.

2. Ischemic stroke patients will be enrolled within 1 month after stroke onset.

3. Patients will be visited at 0m, 1m, 3m, 6m, 9m, 12m, 18m and 24m.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02041117
Study type	Interventional
Source	Beijing Tiantan Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	February 24, 2014
Completion date	November 6, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01819597` - Surgical Indirect Revascularization For Symptomatic Intracranial Arterial Stenosis	N/A
Recruiting	`NCT05844176` - Intracranial Arterial Stenosis in Young Patients
Enrolling by invitation	`NCT04240119` - Angiogenic Markers in Cerebrovascular Disease (ANFIS)
Recruiting	`NCT01553643` - A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial Arterial Stenosis	Phase 4
Completed	`NCT01570231` - Feasibility, Safety and Efficacy of Remote Ischemic Preconditioning for Symptomatic Intracranial Arterial Stenosis in Octogenarians	Phase 1